TYK MEDICINES-B (02410) announced that Sichuan Huiyu Pharmaceutical Co., Ltd. (Sichuan Huiyu) published an announcement on August 26, 2025, regarding its board of directors' approval for Sichuan Huichenxin Pharmaceutical Co., Ltd. (Sichuan Huichenxin), a wholly-owned subsidiary of Sichuan Huiyu, to enter into a potential general agency agreement with the Company for TY-9591, the Company's core product.

Under the potential general agency arrangement, the Company may agree to appoint Sichuan Huichenxin as the exclusive general agent for TY-9591 in China (excluding Hong Kong, Macau, Taiwan, and any other overseas regions), with initial milestone payments of up to RMB 150 million.

As the Group is about to enter the commercialization phase of TY-9591, if the potential general agency arrangement is implemented, the Group will be able to leverage the extensive existing sales and agency networks of Sichuan Huichenxin and Sichuan Huiyu. Sichuan Huiyu is an established pharmaceutical enterprise with a complete industrial chain and extensive experience in pharmaceutical agency and sales in China.

Therefore, the Company believes that this arrangement will help enhance the sales and revenue of TY-9591, accelerate market penetration, reduce the Group's costs in establishing new sales channels, and strengthen the Group's brand image through collaboration with a renowned pharmaceutical company.